Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 401–500 of 2,517
Weirauch, M. T., & Hughes, T. R. (2011) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-90-481-9069-0_3 · Cited by 151
“p53 (p53) 1TSR [48] MADS box (SRF) 1SRS [183] T-box (Bracyury/T) 1XBR [205]”
BackgroundInhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells
Lin, J., Yang, Q., Yan, Z., Markowitz, J., Wilder, P. T., Carrier, F., & Weber, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405419200 · Cited by 129
Robson, M. E., Boyd, J. A., Borgen, P. I., & Cody, H. S. (2001) · Current Problems in Surgery · doi:10.1016/s0011-3840(01)70035-4 · Cited by 136
Harris, C. C. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104s3435 · Cited by 158
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity
Okorokov, A. L., Sherman, M. B., Plisson, C., Grinkevich, V., Sigmundsson, K., Selivanova, G., Milner, J., & Orlova, E. V. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601382 · Cited by 110
“Docking of the core domain atomic structure into p53 EM map We used the atomic structures of the core domain determined for both human and murine p53 (1tup, Cho et al, 1994; 1hu8, Zhao et al, 2001) to identify the location of this domain within the EM structure.”
BackgroundMethodInfluentialPrognostic significance of p53 mutations in colon cancer at the population level
Samowitz, W. S., Curtin, K., Ma, K., Edwards, S., Schaffer, D., Leppert, M. F., & Slattery, M. L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10405 · Cited by 128
Vaishnavi, K., Saxena, N., Shah, N., Singh, R., Manjunath, K., Uthayakumar, M., Kanaujia, S. P., Kaul, S. C., Sekar, K., & Wadhwa, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044419 · Cited by 128
“Interestingly, Arg 282 has been shown to be essential for the stability of protein [40–43] and is one of the mutation ‘‘hot spots’’.”
BackgroundThe isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation
Chen, L., Rashid, F., Shah, A., Awan, H. M., Wu, M., Liu, A., Wang, J., Zhu, T., Luo, Z., & Shan, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502159112 · Cited by 133
“Actually, more than half of human cancer cases relate to mutations in p53, and the single amino acid substitution p53R175H is one of the mutations at the p53R175 hot spot (20, 21).”
BackgroundInfluentialNagaich, A. K., Zhurkin, V. B., Durell, S. R., Jernigan, R. L., Appella, E., & Harrington, R. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.1875 · Cited by 127
Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.
Balagurumoorthy, P., Sakamoto, H., Lewis, M. S., Zambrano, N., Clore, G. M., Gronenborn, A. M., Appella, E., & Harrington, R. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8591 · Cited by 126
Waterman, J. L. F., Shenk, J. L., & Halazonetis, T. D. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07027.x · Cited by 144
Helix bending as a factor in protein/DNA recognition
Dickerson, R. E., & Chiu, T. K. (1997) · Biopolymers · doi:10.1002/(sici)1097-0282(1997)44:4<361::aid-bip4>3.0.co;2-x · Cited by 146
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Role of Rad51 and DNA repair in cancer: A molecular perspective
Laurini, E., Marson, D., Fermeglia, A., Aulić, S., Fermeglia, M., & Pricl, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107492 · Cited by 141
Yuen, M., Hughes, R. D., Heneghan, M. A., Langley, P. G., & Norris, S. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8<2190::aid-cncr1562>3.0.co;2-2 · Cited by 19
Multidimensional NMR Methods for Protein Structure Determination
Kanelis, V., Forman-Kay, J. D., & Kay, L. E. (2001) · IUBMB Life · doi:10.1080/152165401317291147 · Cited by 125
“Although structures have been determined for the individual DNA-binding (58) and oligomerization (59, 60) domains, an understanding of the regulation of p53 function by the N-terminal transactivation and C-terminal regulatory domains requires studies on larger fragments.”
BackgroundInfluentialTeifke, J. P., & Löhr, C. V. (1996) · Journal of Comparative Pathology · doi:10.1016/s0021-9975(96)80010-7 · Cited by 142
Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma
Soong, R., Powell, B., Elsaleh, H., Gnanasampanthan, G., Smith, D. R., Goh, H. S., Joseph, D. J., & Iacopetta, B. M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00285-9 · Cited by 122
Small molecules that reactivate mutant p53
Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00454-4 · Cited by 123
“The only exception was the Phe-176 mutant p53 in which a Cys residue at position 176 that holds a Zn atom responsible for shaping the DNA binding domain is lacking [22].”
BackgroundConformation-dependent phosphorylation of p53
Adler, V., Pincus, M. R., Minamoto, T., Fuchs, S. Y., Bluth, M. J., Brandt-Rauf, P. W., Friedman, F. K., Robinson, R. C., Chen, J. M., Wang, X. W., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1686 · Cited by 121
Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
(2007) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 106
Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity
Seemann, S., & Hainaut, P. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208549 · Cited by 132
“Sitespecific DNA binding by p53 depends upon a highly conserved DNA-binding domain that contains a zinc ion, coordinated on cysteines and histidine residues (Cho et al., 1994; Hainaut and Mann, 2001).”
BackgroundRb and TP53 Pathway Alterations in Sporadic and NF1-Related Malignant Peripheral Nerve Sheath Tumors
Birindelli, S., Perrone, F., Oggionni, M., Lavarino, C. E., Pasini, B., Vergani, B., Ranzani, G. N., Pierotti, M. A., & Pilotti, S. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780293 · Cited by 121
“None of the six amino acid substitutions detected in our series occurred in TP53 mutational hot-spot codons (Greenblatt et al, 1994), although, in all but one case (Case 21), they were located in evolutionary highly conserved regions (Cho et al, 1994; Prives, 1994).”
BackgroundDuijf, P. H. G. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.7.799 · Cited by 121
“Based on p53 data (17), the amino acids most important for this interaction in p63 are probably T116, S121 and T199 in the upper monomer, and T169, E229, G230 and Q255 in the lower monomer.”
BackgroundIncreased apoptosis induction by 121F mutant p53
Saller, E., Tom, E., Brunori, M., Otter, M., Estreicher, A., Mack, D. H., & Iggo, R. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4424 · Cited by 130
“Although effects on DNA-binding specificity are to be expected because amino acid 121 is adjacent to a DNA contact residue and amino acid 277 directly contacts DNA (Cho et al., 1994), the p53-binding sites in the promoter of target genes are not simple palindromes that present”
BackgroundInfluentialBørresen‐Dale, A., Lothe, R. A., Meling, G. I., Hainaut, P. L., Rognum, T. O., & Skovlund, E. (1998) · PubMed · Cited by 119
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
“The contact between the DNA-binding domain of p53 and DNA has been identified by crystallographic analysis (10).”
BackgroundDearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 120
Biological contexts for DNA charge transport chemistry
Merino, E. J., Boal, A. K., & Barton, J. K. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.046 · Cited by 122
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
Wilcken, R., Wang, G., Boeckler, F. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211550109 · Cited by 121
“Ft 1⁄4 mðk1 − k2 þ k2 expð−k1tÞ − k1 expð−k2tÞÞ∕ðk1 − k2Þ þ k3t; [2]”
Laptenko, O., Shiff, I., Freed-Pastor, W., Zupnick, A., Mattia, M., Freulich, E., Shamir, I., Kadouri, N., Kahan, T., Manfredi, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.015 · Cited by 119
“This domain has been subjected to extensive biochemical analysis (Laptenko and Prives, 2006) and its structure has been solved (Cañadillas et al., 2006; Cho et al., 1994; Kitayner et al., 2006; Petty et al., 2011).”
BackgroundMethodRedox Signaling and the Control of Cell Growth and Death
Powis, G., Gasdaska, J. R., & Baker, A. F. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60990-4 · Cited by 134
p53: A Cell Cycle Regulator Activated by DNA Damage
Selivanova, G., & Wiman, K. G. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60253-5 · Cited by 128
Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00163.x · Cited by 117
Structure of the p53 Core Domain Dimer Bound to DNA
Ho, W. C., Fitzgerald, M. X., & Marmorstein, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603634200 · Cited by 118
Targeting protein–protein interactions, a wide open field for drug design
Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117
The Function of the Mutant p53-R175H in Cancer
Chiang, Y.-T., Chien, Y.-C., Lin, Y.-H., Wu, H.-H., Lee, D.-F., & Yu, Y.-L. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 117
“On the basis of the crystal structure of the p53–DNA complex [8], hotspots R248 and R273 come into direct contact with DNA, whereas R249 and R282 lie near the DNA contacting interface.”
BackgroundInfluentialp53: Twenty five years understanding the mechanism of genome protection
Gómez-Lázaro, M., Fernández-Gómez, F.-J., & Jordán, J. (2004) · Journal of Physiology and Biochemistry · doi:10.1007/bf03167075 · Cited by 134
Transient fluctuations of intracellular zinc ions in cell proliferation
Li, Y., & Maret, W. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.05.016 · Cited by 126
Buzek, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.11.2340 · Cited by 116
“Cys277 directly contacts the first pyrimidine base in the consensus PyPyPy trinucleotide ( 15 ) and may be more accessible to redox modifications than the zinc-coordinating cysteines (32).”
BackgroundMethodInfluentialShimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L., & Hupp, T. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202296200 · Cited by 116
The Importance of Being Flexible: The Case of Basic Region Leucine Zipper Transcriptional Regulators
Miller, M. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309788452164 · Cited by 142
“GAL4 [78], and p53 tumor suppressor protein [79]), the bipartite DBD of bZIP proteins assumes a well-ordered, stable structure only when bound to a specific DNA site [80,81].”
BackgroundStructural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis
Wei, H., Qu, L., Dai, S., Li, Y., Wang, H., Feng, Y., Chen, X., Jiang, L., Guo, M., Li, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22655-6 · Cited by 114
Zinc and Cancer: Implications for LIV-1 in Breast Cancer
Grattan, B. J., & Freake, H. C. (2012) · Nutrients · doi:10.3390/nu4070648 · Cited by 147
“The maintenance of basal concentrations of P53 occurs through MDM-2 (Mouse Double Minute-2) mediated ubiquitination [148].”
BackgroundInfluentialTargeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 112
p53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Roy, B., Beamon, J., Balint, E., & Reisman, D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.7805 · Cited by 118
“Mutant p53 proteins generally bind to DNA less efficiently and have diminished transactivation activity (16, 67, 68).”
BackgroundKim, A. L., Raffo, A. J., Brandt-Rauf, P. W., Pincus, M. R., Monaco, R., Abarzua, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 114
Structure and function in the p53 family
Arrowsmith, C. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400619 · Cited by 93
“Similarly, the high level of sequence identity among the DNA binding domains and the overlapping DNA-binding specificity suggests that p63 and p73 interact with DNA in a manner similar to that reported by Cho et al, for p53.(17) Nevertheless, there is ample evidence that p53 and p73 differentially regulate transcripti…”
DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Schlereth, K., Beinoraviciute-Kellner, R., Zeitlinger, M. K., Bretz, A. C., Sauer, M., Charles, J. P., Vogiatzi, F., Leich, E., Samans, B., Eilers, M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.037 · Cited by 113
“already indicated that the assembly of four core domains on a straight DNA strand with the experimentally predicted C2 symmetry would be accompanied by steric hindrance between the H1 helices (Cho et al., 1994).”
BackgroundInfluentialEvolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation
Ashur-Fabian, O., Avivi, A., Trakhtenbrot, L., Adamsky, K., Cohen, M., Kajakaro, G., Joel, A., Amariglio, N., Nevo, E., & Rechavi, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404998101 · Cited by 112
Ren, J., Datta, R., Shioya, H., Li, Y., Oki, E., Biedermann, V., Bharti, A. K., & Kufe, D. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110667200 · Cited by 114
How SH3 domains recognize proline
Musacchio, A. (2002) · Advances in protein chemistry · doi:10.1016/s0065-3233(02)61006-x · Cited by 130
A “Twist box” Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation
Piccinin, S., Tonin, E., Sessa, S., Demontis, S., Rossi, S., Pecciarini, L., Zanatta, L., Pivetta, F., Grizzo, A., Sonego, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.003 · Cited by 130
“In agreement with GST pull-down data, docking simulations ruled out a major role for other regions of p53 in the interaction with Twist1, including the p53 ‘‘core domain’’ (Cho et al., 1994) (lowest energy cluster: 55/500 individuals).”
Young, K. H., Weisenburger, D. D., Dave, B. J., Smith, L., Sanger, W., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R. D., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072082 · Cited by 111
Barrow, L. L., van Bokhoven, H., Daack-Hirsch, S., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.559 · Cited by 111
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines
Wasielewski, M., Elstrodt, F., Klijn, J. G. M., Berns, E. M. J. J., & Schutte, M. E. M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9186-z · Cited by 112
“Five of these missense mutations target residues Ser(241), Arg(273) and Arg(280), which are thought to be crucial in the interaction of the wild-type p53 proteins with DNA [18,19].”
BackgroundInfluentialP53 activity is essential for normal development in Xenopus
Wallingford, J. B., Seufert, D. W., Virta, V. C., & Vize, P. D. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00333-2 · Cited by 118
“The original mutant tested, p53Thr280, disrupts an essential base contact in the DNA-binding domain [39,57].”
BackgroundBodian, D. L., McCutcheon, J. N., Kothiyal, P., Huddleston, K., Iyer, R. K., Vockley, J. G., & Niederhuber, J. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094554 · Cited by 113
“The DNA-binding domain of the p53 protein (black) bound to DNA (purple) [84].”
BackgroundThe Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 108
“The centrally located sequence-specific DNA-binding domain (DBD) (amino acid position 101–306) allows binding to DNA and is frequently altered in p53 mutants, hindering its physiological function [25,26].”
BackgroundPrevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni Syndrome
Wong, P., Verselis, S. J., Garber, J. E., Schneider, K. A., DiGianni, L. M., Stockwell, D. H., Li, F. P., & Syngal, S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.014 · Cited by 111
Velasco, J. A., Feijoó, E., Avila, M. A., & Notario, V. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199803)21:3<177::aid-mc5>3.0.co;2-j · Cited by 4
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity
Petty, T. J., Emamzadah, S., Costantino, L., Petkova, I., Stavridi, E. S., Saven, J. G., Vauthey, E., & Halazonetis, T. D. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.127 · Cited by 117
“Several structures of p53 with DNA have been previously determined (Cho et al, 1994; Ho et al, 2006; Malecka et al, 2009; Chen et al, 2010; Kitayner et al, 2006, 2010).”
BackgroundMethodInfluentialMutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M. P., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 108
Gene Regulation by Reactive Oxygen Species
Cimino, F., Esposito, F., Ammendola, R., & Russo, T. (1997) · Current topics in cellular regulation · doi:10.1016/s0070-2137(97)80005-2 · Cited by 118
Hupp, T. R., & Lane, D. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.18165 · Cited by 108
Harris, C. C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.47 · Cited by 120
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 107
Demma, M., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R., Mallams, A., Doll, R., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107
Perwez Hussain, S., & Harris, C. C. (2006) · Journal of Nippon Medical School · doi:10.1272/jnms.73.54 · Cited by 107
Chicken MAR-Binding Protein ARBP Is Homologous to Rat Methyl-CpG-Binding Protein MeCP2
Weitzel, J. M., Buhrmester, H., & Strätling, W. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5656 · Cited by 106
“It is a frequently observed phenomenon among nuclear proteins that the highest sequence conservation occurs in the DNA binding domain; intensively studied examples are the family of nuclear receptors and the tumor suppressor protein p53 (7, 24).”
BackgroundElledge, R. M., & Lee, W. (1995) · BioEssays · doi:10.1002/bies.950171105 · Cited by 118
p53 abnormalities and genomic instability in primary human breast carcinomas.
Eyfjörd, J. E., Thorlacius, S., Steinarsdóttir, M., Valgardsdottir, R., Ogmundsdottir, H. M., & Anamthawat‐Jónsson, K. (1995) · PubMed · Cited by 105
PyInteraph: A Framework for the Analysis of Interaction Networks in Structural Ensembles of Proteins
Tiberti, M., Invernizzi, G., Lambrughi, M., Inbar, Y., Schreiber, G., & Papaleo, E. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400639r · Cited by 101
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer
Rachagani, S., Macha, M. A., Heimann, N., Seshacharyulu, P., Haridas, D., Chugh, S., & Batra, S. K. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.020 · Cited by 110
Zinc: a promising agent in dietary chemoprevention of cancer.
Dhawan, D. K., & Chadha, V. D. (2010) · PubMed Central · Cited by 118
Ectodermal dysplasias: not only ‘skin’ deep
Priolo, M., Silengo, M., Lerone, M., & Ravazzolo, R. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.580601.x · Cited by 106
“A causative gene, mutated in some cases of EEC, has been recently identified, the p63 gene, which encodes a protein homologous to p53 (11, 92).”
Backgroundneu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J., & Perkins, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3155 · Cited by 105
“Some of the most commonly mutated amino acids are those that make direct contact with the DNA (8).”
BackgroundHuang, F., Rajagopalan, S., Settanni, G., Marsh, R. J., Armoogum, D. A., Nicolaou, N., Bain, A. J., Lerner, E., Haas, E., Ying, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909644106 · Cited by 108
Maruyama, H., Yasui, T., Ishikawa‐Fujiwara, T., Morii, E., Yamamoto, Y., Yoshii, T., Takenaka, Y., Nakahara, S., Todo, T., Hongyo, T., et al. (2014) · Cancer Science · doi:10.1111/cas.12369 · Cited by 105
Boysen, M., Kityk, R., & Mayer, M. P. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.032 · Cited by 105
Vise, P. D. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki336 · Cited by 103
p53 activates ICAM‐1 (CD54) expression in an NF‐κB‐independent manner
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Kletsas, D., Mariatos, G., Zoumpourlis, V., Ryan, K. M., Kittas, C. N., & Papavassiliou, A. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg157 · Cited by 112
“Although each of these putative elements diverged from the consensus p53-binding site by three nucleotides, the central C(A/T)(T/A)G motif, which is crucial for DNA binding (Cho et al., 1994), was intact in all of them.”
Backgroundp53 responsive elements in human retrotransposons
Harris, C. R., DeWan, A., Zupnick, A., Normart, R., Gabriel, A., Prives, C., Levine, A. J., & Hoh, J. (2009) · Oncogene · doi:10.1038/onc.2009.246 · Cited by 102
“On the basis of X-ray crystallography of the p53–DNA complex, the most critical bases in -’ are the 6-nt 50-RCWWGY-30, which come into close contact with the core DNA-binding domain of the p53 protein (Cho et al., 1994).”
BackgroundChrisanthar, R., Knappskog, S., Løkkevik, E., Anker, G. B., Østenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., Skjønsberg, G., Aas, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019249 · Cited by 115
“Twenty-four of the mutations; 12 in the epirubicin cohort and 12 in the paclitaxel cohort, directly or indirectly affected the L2/L3 domains of the p53 protein critical to DNA binding [14], previously found to predict a poor prognosis in general [15] and drug resistance to anthracyclines and mitomycin in particular [1…”
BackgroundLevine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., & Epstein, C. B. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb12115.x · Cited by 116
Honda, K., Sbisà, E., Tullo, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.126 · Cited by 105
“Structural studies have demonstrated that the core domain alone binds, as a monomer, to DNA with sequence specificity and affinity similar to that of complete p53, however the formation of the tetramer is a crucial event for p53 function (Cho et al, 1994).”
BackgroundInfluentialMutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling
Rahnamoun, H., Lu, H., Duttke, S. H., Benner, C., Glass, C. K., & Lauberth, S. M. (2017) · Nature Communications · doi:10.1038/s41467-017-01117-y · Cited by 104
Leroy, K., Haïoun, C., Lepage, É., Metayer, N. L., Berger, F., Labouyrie, E., Meignin, V., Petit, B., Bastard, C., Salles, G. A., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf185 · Cited by 103
“In response to various internal or external signals, such as hypoxia, DNA damage or oncogenic stimulus, the wild-type p53 protein undergoes posttranslational modifications, accumulates within the nucleus of the cells and induces cell cycle arrest or apoptosis [10].”
BackgroundInfluentialMutation analysis of P73 and TP53 in Merkel cell carcinoma
Gele, M. V., Kaghad, M., Leonard, J. H., Roy, N. V., Naeyaert, J. M., Geerts, M. L., Belle, S. V., Cocquyt, V. F. J., Bridge, J. A., Sciot, R., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1006 · Cited by 112
“For the particular amino acid substitutio residue 241, Cho et al (1994) could show that DNA contact not possible as the defective TP53 protein was unable to m contact with the phosphate backbone in the major groove o DNA.”
BackgroundAlsner, J., Sørensen, S. B., & Overgaard, J. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00301-2 · Cited by 103
Shenk, J. L., Fisher, C. J., Chen, S.-Y., Zhou, X.-F., Tillman, K., & Shemshedini, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103652200 · Cited by 103
Mutation of Phosphoserine 389 Affects p53 Function in Vivo
Hao, M., Lowy, A. M., Kapoor, M., Deffie, A., Liu, G., & Lozano, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.29380 · Cited by 102
Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D., Augeri, D., David Kimball, S., Loh, S. N., & Carpizo, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2432 · Cited by 102
“Structural studies of WT p53 have shown that p53 requires a single zinc ion (coordinated by four amino acids C176, H179 on the L2 loop, and C238, and C242 on the L3 loop) for proper folding [10, 11].”
p53 Gene Mutation and Protein Accumulation during Neoplastic Progression in Barrett's Esophagus
Bian, Y., Osterheld, M., Bosman, F. T., et al. (2001) · Modern Pathology · doi:10.1038/modpathol.3880324 · Cited by 102
“tations occur in Exons 5 to 9, which encode the DNA-binding domain (36).”
BackgroundMolecular basis of inherited diseases: a structural perspective
Steward, R. E., MacArthur, M. W., Laskowski, R. A., & Thornton, J. M. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00195-1 · Cited by 113
“One such hotspot ‐ arginine 273 ‐ contacts the DNA phosphate backbone (Fig. 5d) with its charged side-chain [ 24 ], and its mutation to histidine is associated with Li-Fraumeni syndrome [25] and low p53 DNA-binding.”
BackgroundNagata, Y., Anan, T., Yoshida, T., Mizukami, T., Taya, Y., Fujiwara, T., Kato, H., Saya, H., & Nakao, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202978 · Cited by 101
“Although missense mutations in cancers occur at several di erent codons, most mt p53 proteins obtain a commonly mutated conformation which is reactive to an anti-p53 monoclonal antibody, Pab240 (Gannon et al., 1990; a b c d Cho et al., 1994).”
BackgroundImmunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.
Werner, M. H., Nagata, T., Gupta, V., Sorce, D., Kim, W., Šali, A., Chait, B. T., Shigesada, K., & Ito, Y. (1999) · Nature Structural Biology · doi:10.1038/10658 · Cited by 101
Bayle, J. H., Elenbaas, B., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5729 · Cited by 102
Nishio, K., & Inoue, A. (2005) · Histochemistry and Cell Biology · doi:10.1007/s00418-005-0766-5 · Cited by 121
“PAb240 binds specifically to a conformationally altered or a partially denatured p53 (Cho et al. 1994).”
BackgroundInfluential
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.